B+
Bull case
20%
Probability
Target price
$32.98
Analysis reference price unavailable
Analysis 2026-02-07 · RankAlpha Sentiment AI
ROIV
Roivant SciencesFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment AIMost likely
B
Base case
60%
Probability
Target price
$25.37
Analysis reference price unavailable
Analysis 2026-02-07 · RankAlpha Sentiment AI
B-
Bear case
20%
Probability
Target price
$20.30
Analysis reference price unavailable
Analysis 2026-02-07 · RankAlpha Sentiment AI
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-02-07
Recent news sentiment (30D)
-
Unavailable
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+17.5
Score
AI commentary
Market consensus shows a mixed-to-neutral positioning with median analyst targets near current levels; coverage includes a range from low (~$20) to high (~$34) that implies divergent views [#SERP-3], [#SERP-5]. Short-term sentiment may hinge on upcoming corporate updates and coverage refreshes, while longer-term tone will track clinical readouts and capital dynamics [#SERP-2].
RankAlpha Sentiment AI - 2026-02-07
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-03-31eventAnalyst coverage refreshHigh impact
Consensus and target updates from coverage changes that can shift headline targets and sentiment; date set to the assumed refresh window end [#SERP-4].
2026-05-08catalystQuarterly/corporate updateHigh impact
Quarterly results or a corporate update that could change guidance or cash outlook; conservatively dated when no formal SEC date exists [#SERP-3].
2027-02-07catalystMajor clinical/regulatory milestoneHigh impact
A pivotal clinical readout or regulatory decision for a lead asset that would materially re-rate valuation; timeline set conservatively when no single public date is available [#SERP-2][#SERP-5].
Recommendation
N/A
No formal recommendation provided.
As of 2026-02-07 • Updated nightlySource: Internal modelMethodology